Annals of clinical and translational neurology · 2025
Plasma p-tau181 as a Marker of Conversion to Alzheimer's Disease Dementia and Worsening in Cognitive Functions in Subjective Cognitive Decline and Mild Cognitive Impairment: A Longitudinal Study.
СтатьяПоддержка исследования: вне правительства СШАНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Giacomucci Giulia, Ingannato Assunta, Crucitti Chiara, Bagnoli Silvia, Marcantelli Elisa, Padiglioni Sonia, Moschini Valentina, Morinelli Carmen, Falsini Laura, Sorbi Sandro, Berti Valentina, Nacmias Benedetta, Bessi Valentina
Аннотация
BACKGROUND: Plasma p-tau181 has proven to be a promising diagnostic and prognostic tool in the earliest phases of Alzheimer's disease (AD). We aimed to evaluate the prognostic role of p-tau181 in predicting conversion to AD dementia and worsening in cognition in mild cognitive impairment (MCI) and subjective cognitive decline (SCD).
METHODS: We consecutively enrolled 163 patients (50 SCD, 70 MCI, and 43 AD-demented (AD-d)), who underwent plasma p-tau181 analysis with the Simoa assay. Patients were classified according to the Revised Criteria of the Alzheimer's Association Workgroup as Core1+ or Core1- (based on amyloid-PET, CSF Aβ42/Aβ40, CSF p-tau181/Aβ42).
RESULTS: Plasma p-tau181 levels were significantly influenced by Core1 status (B = 1.41, p < 0.001) and clinical diagnosis (B = 0.63, p < 0.001). Plasma p-tau181 was highly accurate in discriminating between Core1+ and Core1- patients (AUC = 0.88 [95% CI 83.00-94.00]) with a cut-off value of 2.25 pg/mL presenting good accuracy (85.90%), specificity (74.58%), and excellent sensitivity (92.78%). Classifying patients according to p-tau181 cut-off, we found that p-tau181+ patients showed an increased risk of converting to AD dementia (HR = 11.65, p = 0.018). Moreover, SCD p-tau181+ worsened over time in tasks assessing long-term verbal (p = 0.012) and spatial memory (p = 0.009).
CONCLUSIONS: Plasma p-tau181 is not only a good diagnostic marker for AD pathology, but it also plays a role as a predictor of both conversion to AD dementia and of worsening of cognitive performance since the earliest phase of AD.
METHODS: We consecutively enrolled 163 patients (50 SCD, 70 MCI, and 43 AD-demented (AD-d)), who underwent plasma p-tau181 analysis with the Simoa assay. Patients were classified according to the Revised Criteria of the Alzheimer's Association Workgroup as Core1+ or Core1- (based on amyloid-PET, CSF Aβ42/Aβ40, CSF p-tau181/Aβ42).
RESULTS: Plasma p-tau181 levels were significantly influenced by Core1 status (B = 1.41, p < 0.001) and clinical diagnosis (B = 0.63, p < 0.001). Plasma p-tau181 was highly accurate in discriminating between Core1+ and Core1- patients (AUC = 0.88 [95% CI 83.00-94.00]) with a cut-off value of 2.25 pg/mL presenting good accuracy (85.90%), specificity (74.58%), and excellent sensitivity (92.78%). Classifying patients according to p-tau181 cut-off, we found that p-tau181+ patients showed an increased risk of converting to AD dementia (HR = 11.65, p = 0.018). Moreover, SCD p-tau181+ worsened over time in tasks assessing long-term verbal (p = 0.012) and spatial memory (p = 0.009).
CONCLUSIONS: Plasma p-tau181 is not only a good diagnostic marker for AD pathology, but it also plays a role as a predictor of both conversion to AD dementia and of worsening of cognitive performance since the earliest phase of AD.